HK Stock Market Move | JUNSHI BIO (01877) rose more than 4%; Tislelizumab monoclonal antibody approved for market listing by UK MHRA.

JUNSHI BIO (01877) rose more than 4%, up 4.05% at the time of writing, to 12.86 Hong Kong dollars, with a trading volume of 6.302 million Hong Kong dollars. On the news front, JUNSHI BIO announced that its wholly-owned subsidiary's product Toripalimab (trade name in the UK: LOQTORZI) has received approval for marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA). It is approved for the treatment of two indications: 1. Toripalimab in combination with cisplatin and fluorouracil for first-line treatment of recurrent, unresectable or radiotherapy-refractory, or metastatic nasopharyngeal carcinoma in adult patients; 2. Toripalimab in combination with cisplatin and paclitaxel for first-line treatment of unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma in adult patients. Toripalimab has become the first and only drug in the UK approved for the treatment of nasopharyngeal carcinoma and the only first-line treatment drug for unresectable advanced or metastatic esophageal squamous cell carcinoma with unlimited PD-L1 expression in the UK.